Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEKS-cUTI: Cefiderocol in Complicated Urinary Tract Infections
NCT02321800Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cefiderocol in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Composite Response of Microbiological Eradication and Clinical Response. Started Feb 2015; status: completed.
02
Drugs
cefiderocol
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT02321800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321800.